SUBSCRIBERS
Johnson & Johnson's Stelara shows promise against lupus in study
Published Mon, Nov 6, 2017 · 09:50 PM
San Diego
JOHNSON & Johnson's blockbuster psoriasis drug Stelara led to a significant reduction in disease activity in patients with systemic lupus compared with a placebo in a mid-stage clinical trial, according to data released on Saturday.
Stelara, a biotech drug known chemically as ustekinumab, is already approved for psoriasis, psoriatic arthritis and Crohn's disease and had third-quarter sales of US$1.12 billion.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Indian winemaker Sula Vineyards' Q4 profit slips on mounting expenses
Olam tops Louis Dreyfus’ offer for Australia’s Namoi Cotton as takeover battle heats up
Puma returns to sales growth in Americas despite ‘volatile’ market
Nanjing Xinjiekou Department Store announces May 23 EGM; Cordlife seeking legal advice
Cutting the cord?: Events leading up to Cordlife’s MOH suspension and arrests of its directors, ex-group CEO
‘Limits’ to MOH intervention for Cordlife customer refunds, compensation: Janil